Propranolol in the preoperative treatment of Kasabach-Merritt syndrome: a case report

J Med Case Rep. 2017 Oct 27;11(1):308. doi: 10.1186/s13256-017-1475-0.

Abstract

Background: Kasabach-Merritt syndrome represents the association of hemangioma with thrombocytopenia and consumptive coagulopathy. We present a case of Kasabach-Merritt syndrome treatment with orally administered propranolol.

Case presentation: A 4.5-month-old caucasian female infant with congenital giant hemangioma in the posterior region of her neck presented to our Institute for Childhood Diseases where she underwent clinical, laboratory, and radiological investigations. A low blood platelet count indicated the use of corticosteroids and blood components as first-line therapy. The lack of therapeutic response induced the introduction of orally administered propranolol as additive therapy. A 3-week treatment led to a reduction in the size of hemangioma and a rise in platelet count which enabled surgical treatment and definite healing.

Conclusion: Orally administered propranolol as monotherapy or in combination with other therapeutic modalities may play a key role in the treatment of Kasabach-Merritt syndrome.

Keywords: Hemangioma; Infant; Kasabach–Merritt syndrome; Platelets; Propranolol.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Combined Modality Therapy / methods
  • Female
  • Humans
  • Infant
  • Kasabach-Merritt Syndrome / drug therapy*
  • Kasabach-Merritt Syndrome / surgery*
  • Preoperative Care / methods*
  • Propranolol / therapeutic use*
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Propranolol